Custirsen | CAS# 890056-27-6 | cancer

MedKoo Cat#: 414555 | Name: Custirsen

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Custirsen is an investigational drug that was under clinical testing for the treatment of cancer. It is an antisense oligonucleotide targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving over all survival.

Chemical Structure

Custirsen

CAS#890056-27-6

Theoretical Analysis

MedKoo Cat#: 414555

Name: Custirsen

CAS#: 890056-27-6

Chemical Formula: C231H312N78O119P20S20

Exact Mass: 7340.9927

Molecular Weight: 7346.14

Elemental Analysis: C, 37.77; H, 4.28; N, 14.87; O, 25.92; P, 8.43; S, 8.73

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Custirsen; OGX011 Parent Acid; OGX-011 Parent Acid; OGX 011 Parent Acid

IUPAC/Chemical Name

m5Cyt-MeOEt(-2)Ribf-sP-Ade-MeOEt(-2)Ribf-sP-Gua-MeOEt(-2)Ribf-sP-m5Cyt-MeOEt(-2)Ribf-sP-dAdo-sP-dGuo-sP-dCyd-sP-dAdo-sP-dGuo-sP-dAdo-sP-dGuo-sP-dThd-sP-dCyd-sP-dThd-sP-dThd-sP-dCyd-sP-dAdo-sP-Thy-MeOEt(-2)Ribf-sP-m5Cyt-MeOEt(-2)Ribf-sP-Ade-MeOEt(-2)Ribf-sP-Thy-MeOEt(-2)Ribf

InChi Key

RCFZILUHCNXXFY-DEDWCYLFSA-N

InChi Code

InChI=1S/C231H312N78O119P20S20/c1-97-52-295(224(324)273-181(97)235)210-174(361-32-24-353-10)166(118(60-310)401-210)422-444(347,464)383-78-136-171(179(366-37-29-358-15)215(406-136)308-95-265-160-189(243)253-86-259-195(160)308)427-448(351,468)387-80-138-172(180(367-38-30-359-16)216(408-138)309-96-269-164-199(309)279-220(247)283-208(164)320)428-447(350,467)385-76-134-168(175(362-33-25-354-11)211(403-134)296-53-98(2)182(236)274-225(296)325)423-442(345,462)380-73-131-114(48-151(397-131)303-90-263-158-187(241)251-84-257-193(158)303)417-439(342,459)379-72-128-115(49-152(398-128)304-91-266-161-196(304)276-217(244)280-205(161)317)418-435(338,455)370-63-121-107(41-144(390-121)291-22-19-141(234)272-223(291)323)411-430(333,450)374-67-125-111(45-148(394-125)300-87-260-155-184(238)248-81-254-190(155)300)415-437(340,457)378-71-130-117(51-154(400-130)306-93-268-163-198(306)278-219(246)282-207(163)319)420-440(343,460)376-68-126-112(46-149(395-126)301-88-261-156-185(239)249-82-255-191(156)301)416-438(341,458)377-70-129-116(50-153(399-129)305-92-267-162-197(305)277-218(245)281-206(162)318)419-436(339,456)373-66-124-109(43-146(393-124)293-56-101(5)201(313)285-228(293)328)413-433(336,453)368-61-119-105(39-142(388-119)289-20-17-139(232)270-221(289)321)409-429(332,449)371-64-122-110(44-147(391-122)294-57-102(6)202(314)286-229(294)329)414-434(337,454)372-65-123-108(42-145(392-123)292-55-100(4)200(312)284-227(292)327)412-432(335,452)369-62-120-106(40-143(389-120)290-21-18-140(233)271-222(290)322)410-431(334,451)375-69-127-113(47-150(396-127)302-89-262-157-186(240)250-83-256-192(157)302)421-441(344,461)382-75-133-167(177(364-35-27-356-13)213(405-133)299-59-104(8)204(316)288-231(299)331)424-445(348,465)384-77-135-169(176(363-34-26-355-12)212(404-135)297-54-99(3)183(237)275-226(297)326)425-446(349,466)386-79-137-170(178(365-36-28-357-14)214(407-137)307-94-264-159-188(242)252-85-258-194(159)307)426-443(346,463)381-74-132-165(311)173(360-31-23-352-9)209(402-132)298-58-103(7)203(315)287-230(298)330/h17-22,52-59,81-96,105-138,142-154,165-180,209-216,310-311H,23-51,60-80H2,1-16H3,(H,332,449)(H,333,450)(H,334,451)(H,335,452)(H,336,453)(H,337,454)(H,338,455)(H,339,456)(H,340,457)(H,341,458)(H,342,459)(H,343,460)(H,344,461)(H,345,462)(H,346,463)(H,347,464)(H,348,465)(H,349,466)(H,350,467)(H,351,468)(H2,232,270,321)(H2,233,271,322)(H2,234,272,323)(H2,235,273,324)(H2,236,274,325)(H2,237,275,326)(H2,238,248,254)(H2,239,249,255)(H2,240,250,256)(H2,241,251,257)(H2,242,252,258)(H2,243,253,259)(H,284,312,327)(H,285,313,328)(H,286,314,329)(H,287,315,330)(H,288,316,331)(H3,244,276,280,317)(H3,245,277,281,318)(H3,246,278,282,319)(H3,247,279,283,320)/t105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,209+,210+,211+,212+,213+,214+,215+,216+,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?,440?,441?,442?,443?,444?,445?,446?,447?,448?/m0/s1

SMILES Code

COCCO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=C(C(NC2=O)=O)C)COP(S)(O[C@@H]3[C@H](O[C@@H](n4c5ncnc(N)c5nc4)[C@@H]3OCCOC)COP(S)(O[C@@H]6[C@H](O[C@@H](N7C=C(C(N)=NC7=O)C)[C@@H]6OCCOC)COP(S)(O[C@@H]8[C@H](O[C@@H](N9C=C(C(NC9=O)=O)C)[C@@H]8OCCOC)COP(S)(O[C@H]%10C[C@H](n%11c%12ncnc(N)c%12nc%11)O[C@@H]%10COP(S)(O[C@H]%13C[C@H](N%14C=CC(N)=NC%14=O)O[C@@H]%13COP(S)(O[C@H]%15C[C@H](N%16C=C(C(NC%16=O)=O)C)O[C@@H]%15COP(S)(O[C@H]%17C[C@H](N%18C=C(C(NC%18=O)=O)C)O[C@@H]%17COP(S)(O[C@H]%19C[C@H](N%20C=CC(N)=NC%20=O)O[C@@H]%19COP(S)(O[C@H]%21C[C@H](N%22C=C(C(NC%22=O)=O)C)O[C@@H]%21COP(S)(O[C@H]%23C[C@H](n%24c%25c(C(NC(N)=N%25)=O)nc%24)O[C@@H]%23COP(S)(O[C@H]%26C[C@H](n%27c%28ncnc(N)c%28nc%27)O[C@@H]%26COP(S)(O[C@H]%29C[C@H](n%30c%31c(C(NC(N)=N%31)=O)nc%30)O[C@@H]%29COP(S)(O[C@H]%32C[C@H](n%33c%34ncnc(N)c%34nc%33)O[C@@H]%32COP(S)(O[C@H]%35C[C@H](N%36C=CC(N)=NC%36=O)O[C@@H]%35COP(S)(O[C@H]%37C[C@H](n%38c%39c(C(NC(N)=N%39)=O)nc%38)O[C@@H]%37COP(S)(O[C@H]%40C[C@H](n%41c%42ncnc(N)c%42nc%41)O[C@@H]%40COP(S)(O[C@@H]%43[C@H](O[C@@H](N%44C=C(C(N)=NC%44=O)C)[C@@H]%43OCCOC)COP(S)(O[C@@H]%45[C@H](O[C@@H](n%46c%47c(C(NC(N)=N%47)=O)nc%46)[C@@H]%45OCCOC)COP(S)(O[C@@H]%48[C@H](O[C@@H](n%49c%50ncnc(N)c%50nc%49)[C@@H]%48OCCOC)COP(S)(O[C@@H]%51[C@H](O[C@@H](N%52C=C(C(N)=NC%52=O)C)[C@@H]%51OCCOC)CO)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 7,346.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Chi KN, Zoubeidi A, Gleave ME. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs. 2008 Dec;17(12):1955-62. doi: 10.1517/13543780802528609. PMID: 19012510. 2: Sidaway P. Prostate cancer: Custirsen fails to improve outcomes. Nat Rev Urol. 2017 Jun;14(6):327. doi: 10.1038/nrurol.2017.51. Epub 2017 Mar 29. PMID: 28352135. 3: Chi KN, Higano CS, Blumenstein B, Ferrero JM, Reeves J, Feyerabend S, Gravis G, Merseburger AS, Stenzl A, Bergman AM, Mukherjee SD, Zalewski P, Saad F, Jacobs C, Gleave M, de Bono JS. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2017 Apr;18(4):473-485. doi: 10.1016/S1470-2045(17)30168-7. Epub 2017 Mar 8. PMID: 28283282. 4: Al-Asaaed S, Winquist E. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer. Curr Oncol Rep. 2013 Apr;15(2):113-8. doi: 10.1007/s11912-012-0285-1. PMID: 23266703. 5: Zhang X, Liu C, Li K, Wang K, Zhang Q, Cui Y. Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer. Medicine (Baltimore). 2019 Feb;98(6):e14254. doi: 10.1097/MD.0000000000014254. PMID: 30732140; PMCID: PMC6380863. 6: Wilson MR, Zoubeidi A. Clusterin as a therapeutic target. Expert Opin Ther Targets. 2017 Feb;21(2):201-213. doi: 10.1080/14728222.2017.1267142. Epub 2016 Dec 16. PMID: 27978767. 7: Edwards AY, Elgart A, Farrell C, Barnett-Griness O, Rabinovich-Guilatt L, Spiegelstein O. A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects. Br J Clin Pharmacol. 2017 Sep;83(9):1932-1943. doi: 10.1111/bcp.13287. Epub 2017 May 2. PMID: 28294391; PMCID: PMC5555861. 8: Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9. PMID: 29033099. 9: Thoma C. Prostate cancer: No benefit of combining custirsen with cabazitaxel. Nat Rev Urol. 2017 Dec;14(12):700. doi: 10.1038/nrurol.2017.193. Epub 2017 Nov 8. PMID: 29116255. 10: Rabinovich-Guilatt L, Elgart A, Erisson L, Willsie SK, Tessler S, Barnett- Griness O, Pande A, Spiegelstein O. Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects. Br J Clin Pharmacol. 2015 Sep;80(3):436-45. doi: 10.1111/bcp.12633. Epub 2015 Jun 22. PMID: 25782535; PMCID: PMC4574829.